Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other non-current liabilities of $678K in Q2 FY2026

Q2 FY2026 other non-current liabilities was $678K.

Context

  • Other non-current liabilities amounted to 0.5% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$678K-9.6% QoQ
Last fiscal yearDec 2025
$755K-89.0% YoY
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-89.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
755K USD
Year-over-year change
-89.0%
1-year CAGR
-89.0%

Other Non-current Liabilities vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Other non-current liabilities amounts to 0.5% of total assets for ATTO, versus a peer median of 0.1%.
ATTO Competitors
Other Non-current Liabilities for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACRSAclaris Therapeutics, Inc.Mar 2026$11M USD-64.0%-31.8%5.5%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€8.11M EUR——4.9%
QTTBQ32 Bio Inc.Mar 2026$1.94M USD-96.5%—3.0%
ATTOAttovia Therapeutics, Inc.Jun 2026$678K USD——0.5%
MLTXMoonLake ImmunotherapeuticsMar 2026$353K USD-34.1%—0.1%
ALMSAlumis Inc. Common StockJun 2026$239K USD-56.9%-89.6%0.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$114K USD-82.0%—0.2%
ORKAOruka Therapeutics, Inc.Sep 2026$0 USD——0.0%
ANABAnaptysBio, Inc.Mar 2026$0 USD-100.0%-3.2%0.0%
EVMNEvommune, Inc.Mar 2026$0 USD-100.0%—0.0%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
Peer median (excluding ATTO) —-82.0%-31.8%0.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.